. 2021 Jul 27;11:670396. doi: 10.3389/fonc.2021.670396
Copyright © 2021 Striefler, Riess, Lohneis, Bischoff, Kurreck, Modest, Bahra, Oettle, Sinn, Bläker, Denkert, Stintzing, Sinn and Pelzer
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Figure 3.
Survival analyses in subgroups for (A–D) MUC1 low vs. high, and gemcitabine vs. observation (E–H).